OpGen (NASDAQ:OPGN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of OpGen (NASDAQ:OPGNFree Report) in a research report released on Saturday morning. The firm issued a sell rating on the medical research company’s stock.

OpGen Trading Down 2.7 %

NASDAQ:OPGN opened at $0.40 on Friday. The stock has a 50 day simple moving average of $0.38 and a 200 day simple moving average of $0.41. The stock has a market cap of $4.00 million, a P/E ratio of -0.06 and a beta of -0.90. OpGen has a 1-year low of $0.17 and a 1-year high of $3.84.

OpGen (NASDAQ:OPGNGet Free Report) last posted its quarterly earnings data on Tuesday, November 14th. The medical research company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.03). The firm had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.90 million. OpGen had a negative return on equity of 316.30% and a negative net margin of 852.18%. As a group, sell-side analysts forecast that OpGen will post -2.02 EPS for the current year.

Institutional Trading of OpGen

Several large investors have recently bought and sold shares of OPGN. HRT Financial LP acquired a new stake in shares of OpGen during the fourth quarter valued at about $26,000. Citadel Advisors LLC boosted its stake in shares of OpGen by 571.0% during the third quarter. Citadel Advisors LLC now owns 100,773 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 85,754 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of OpGen during the first quarter valued at about $49,000. Finally, Vanguard Group Inc. boosted its stake in shares of OpGen by 39.8% during the third quarter. Vanguard Group Inc. now owns 1,877,597 shares of the medical research company’s stock valued at $537,000 after purchasing an additional 534,960 shares in the last quarter. 13.07% of the stock is owned by institutional investors and hedge funds.

OpGen Company Profile

(Get Free Report)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Featured Stories

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.